Autopsy report · NCT06626633

2321GCCC: CRD3874-SI in Patients With Relapsed/Refractory AML

“Pharmaceutical Company withdrew support and investigational product”

The sponsor’s own words in the registry.

Life of this trial

• Suspended: paused, and may or may not restart.
• 6 participants enrolled.

Vital statistics

Status

Suspended

Phase

Phase 1

Sponsor

University of Maryland, Baltimore

Sponsor type

University, hospital or other

Conditions

Acute Myeloid Leukemia

Interventions

CRD3874

Participants

6

Sites

1

Countries

United States

Trials that died the same way

• A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus
  “Pharmaceutical sponsor withdrew financial support.” (76% match in meaning)
• A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma
  “Pharmaceutical company pulled support for the trial.” (72% match in meaning)
• MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
  “Product withdrawn from clinical development” (71% match in meaning)
• Beta Cell Rescue in New Onset Type 1 Diabetes With Efalizumab
  “drug withdrawn from market” (70% match in meaning)
• Panobinostat/Velcade in Multiple Myeloma
  “This study was terminated because the drug company stopped making the study drug” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.